Charles River buys Frontage bioanalysis units for $470 million
Alpha Vantage · Benzinga · · AI-summarised by FinFlash
Charles River Laboratories will acquire Frontage Holdings' bioanalysis and DMPK operations for $470 million in cash, plus up to $75 million in earnouts. The deal expands Charles River's clinical bioanalysis capabilities, balances its lab testing portfolio and targets the growing global bioanalysis market. William Blair calls it an attractive strategic addition.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.